James K. Mangan

1.9k total citations
64 papers, 1.1k citations indexed

About

James K. Mangan is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, James K. Mangan has authored 64 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Hematology, 22 papers in Oncology and 18 papers in Genetics. Recurrent topics in James K. Mangan's work include Acute Myeloid Leukemia Research (21 papers), Hematopoietic Stem Cell Transplantation (21 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers). James K. Mangan is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Hematopoietic Stem Cell Transplantation (21 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers). James K. Mangan collaborates with scholars based in United States. James K. Mangan's co-authors include Selina M. Luger, Nancy A. Speck, Elizabeth O. Hexner, Noelle V. Frey, Alison W. Loren, Saar Gill, Edward A. Stadtmauer, Ruben A. Mesa, E. Premkumar Reddy and John Mascarenhas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

James K. Mangan

58 papers receiving 1.0k citations

Peers

Countries citing papers authored by James K. Mangan

Since Specialization

Citations

This map shows the geographic impact of James K. Mangan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James K. Mangan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James K. Mangan more than expected).

Fields of papers citing papers by James K. Mangan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James K. Mangan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James K. Mangan. The network helps show where James K. Mangan may publish in the future.

Co-authorship network of co-authors of James K. Mangan

This figure shows the co-authorship network connecting the top 25 collaborators of James K. Mangan. A scholar is included among the top collaborators of James K. Mangan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James K. Mangan. James K. Mangan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept 2025 ·Blood Advances ·Divya Koura, (unknown), Aaron M. Goodman, Caitlin Costello, Carolyn Mulroney, James K. Mangan, Tiffany Tanaka, Edward D. Ball, Ayad Hamdan, (unknown), James Mirocha, (unknown), (unknown), (unknown), (unknown), (unknown), Gerald P. Morris, Dimitrios Tzachanis	0
2	IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine 2023 ·Leukemia Research Reports ·(unknown), Huan‐You Wang, (unknown), Brian Hinds, James K. Mangan	0
3	Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703. 2023 ·Journal of Clinical Oncology ·Matthew J. Wieduwilt, Jun Yin, (unknown), Rebecca Teske, Wendy Stock, (unknown), (unknown), James K. Mangan, Gregory A. Masters, Alice S. Mims, Katarzyna Jamieson, Shira Dinner, (unknown), Geoffrey L. Uy, Harry P. Erba, Mark R. Litzow, Richard M. Stone	22
4	A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus 2023 ·Blood ·Divya Koura, James Mirocha, (unknown), Ayad Hamdan, Aaron M. Goodman, Tiffany Tanaka, Carolyn Mulroney, Caitlin Costello, James K. Mangan, Edward D. Ball, (unknown), (unknown), (unknown), Dimitrios Tzachanis	1
5	Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies 2022 ·Transplantation and Cellular Therapy ·(unknown), Alison W. Loren, Elizabeth O. Hexner, Mary Ellen Martin, Saar Gill, Selina M. Luger, James K. Mangan, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Colleen Timlin, Craig W. Freyer, (unknown), (unknown), Jacqueline Smith, (unknown), Alexis Zebrowski, Edward A. Stadtmauer, David L. Porter, Noelle V. Frey	2
6	FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia 2021 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Ila M. Saunders, James K. Mangan, Aaron M. Goodman	13
7	Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay 2021 ·Transplantation and Cellular Therapy ·Craig W. Freyer, Shannon Gier, (unknown), (unknown), (unknown), Alex Ganetsky, Colleen Timlin, Daria V. Babushok, Noelle V. Frey, Saar Gill, Elizabeth O. Hexner, Alison W. Loren, James K. Mangan, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Jacqueline Smith, Selina M. Luger, Edward A. Stadtmauer, David Porter	2
8	Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome 2019 ·Blood ·Shannon R. McCurdy, Shannon Gier, Daria V. Babushok, Noelle V. Frey, Saar Gill, Elizabeth O. Hexner, Alison W. Loren, James K. Mangan, Mary Ellen Martin, Alexander E. Perl, Ivan Maillard, Keith W. Pratz, David L. Porter, Martin Carroll, Phyllis A. Gimotty, Selina M. Luger	4
9	Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition 2018 ·Investigational New Drugs ·Margaret Kasner, Rosemarie Mick, Grace R. Jeschke, Matthew Carabasi, Joanne Filicko-O’Hara, Neal Flomenberg, Noelle V. Frey, Elizabeth O. Hexner, Selina M. Luger, Alison W. Loren, James K. Mangan, John L. Wagner, Mark A. Weiss, Martin Carroll, Alexander E. Perl	17
10	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial 2018 ·Biology of Blood and Marrow Transplantation ·Ran Reshef, Alex Ganetsky, Edward P. Acosta, (unknown), (unknown), (unknown), Noelle V. Frey, Elizabeth O. Hexner, James A. Hoxie, Alison W. Loren, Selina M. Luger, James K. Mangan, Edward A. Stadtmauer, Rosemarie Mick, Robert H. Vonderheide, David Porter	23
11	Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract 2018 ·Bone Marrow Transplantation ·Alex Ganetsky, Noelle V. Frey, Elizabeth O. Hexner, Alison W. Loren, Saar Gill, Selina M. Luger, James K. Mangan, Mary Ellen Martin, Daria V. Babushok, William R. Drobyski, Jacqueline Smith, Colleen Timlin, Craig W. Freyer, Edward A. Stadtmauer, David Porter	33
12	Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice 2018 ·Blood ·Craig W. Freyer, Alex Ganetsky, Mitchell E. Hughes, (unknown), Colleen Timlin, Noelle V. Frey, Elizabeth O. Hexner, Alison W. Loren, James K. Mangan, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, David L. Porter, Selina M. Luger	2
13	Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia 2018 ·Journal of Oncology Pharmacy Practice ·Craig W. Freyer, James K. Mangan	0
14	Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey 2016 ·BMC Cancer ·Ruben A. Mesa, Carole B. Miller, (unknown), James K. Mangan, (unknown), Salman Fazal, Xiaomei Ma, Wendy Wilson, Dilan Paranagama, (unknown), John Boyle, John Mascarenhas	122
15	Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States 2015 ·Blood ·Shreekant Parasuraman, Ahmad Naim, Dilan Paranagama, (unknown), (unknown), John Mascarenhas, James K. Mangan, Salman Fazal, Carole B. Miller, Ruben A. Mesa	2
16	Acute Cholecystitis Is a Common Complication after Allogeneic Stem Cell Transplantation and Is Associated with the Use of Total Parenteral Nutrition 2014 ·Biology of Blood and Marrow Transplantation ·Stephen Bagley, Alison R. Sehgal, Saar Gill, Noelle V. Frey, Elizabeth O. Hexner, Alison W. Loren, James K. Mangan, David L. Porter, Edward A. Stadtmauer, Ran Reshef, Selina M. Luger	6
17	CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation 2014 ·Blood ·Ran Reshef, Austin P. Huffman, (unknown), (unknown), Marlise R. Luskin, Selina M. Luger, Alison W. Loren, Elizabeth O. Hexner, Sunita D. Nasta, Noelle V. Frey, Saar Gill, James K. Mangan, Lee P. Richman, Taku Kambayashi, Edward A. Stadtmauer, Robert H. Vonderheide, David L. Porter	1
18	RUNX1 Mutations in Clonal Myeloid Disorders: From Conventional Cytogenetics to Next Generation Sequencing, A Story 40 Years in the Making 2011 ·Critical Reviews™ in Oncogenesis ·James K. Mangan, Nancy A. Speck	71
19	Runx1 Loss Minimally Impacts Long-Term Hematopoietic Stem Cells 2011 ·PLoS ONE ·Xiongwei Cai, Justin Gaudet, James K. Mangan, (unknown), Maria Elena De Obaldia, (unknown), Patricia Ernst, Nancy A. Speck	63
20	A UV-sensitive mutant of neurospora defective for photoreactivation 1970 ·Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis ·R. W. Tuveson, James K. Mangan	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact